PT-141 (Bremelanotide)

Melanocortin-receptor agonist

Quick Answer

A synthetic peptide that activates melanocortin receptors in the central nervous system — the only compound in this library, alongside semaglutide/tirzepatide/tesamorelin, with a real, current FDA approval, though for a narrow indication and population.

Why People Are Interested

It's a genuinely FDA-approved compound — one of the few in this library — which makes it a useful, concrete reference point, but its approval is specific to one population and use, and a large share of the current retail/online interest is for off-label use outside that approval.

What People Hope It May Do

Broader sexual-function benefits in men and in women outside the approved population, and general libido enhancement. (Commonly discussed or proposed — not an established, evidence-backed outcome unless separately stated in Human Evidence above; the approved evidence base does not cover these uses.)

Potential / Research Areas

How It May Work

Binds melanocortin receptors (primarily MC4R) in the central nervous system; believed to be associated with sexual-desire pathways, though the FDA-approved label itself describes the mechanism as not fully understood.

What Human Research Shows

Supported by randomized, placebo-controlled Phase 3 trials sufficient for FDA approval in its specific approved indication and population — a meaningfully stronger evidence tier than most compounds in this database. Evidence for other uses (e.g., in men) is comparatively limited and off-label.

What Preclinical Research Shows

Standard preclinical melanocortin-receptor pharmacology/toxicology package preceding its approved human trials, run by Palatin Technologies.

What People Report

What Experts Are Saying

Curated commentary specific to PT-141 (Bremelanotide) is planned as the Expert & Creator Library grows. Being listed there does not imply an expert's endorsement of Element Health Labs.

Clinical Trials

For the current, authoritative list of registered trials involving PT-141 (Bremelanotide), search ClinicalTrials.gov directly — trial status changes frequently, and that registry is the source of truth, not a static summary on this page.

Potential Risks & Side Effects

General information only — not individualized guidance. The approved label lists nausea, flushing, injection-site reactions, and headache as the most common side effects, most transient and mild-to-moderate; actual use requires a licensed prescriber and should follow the FDA-approved labeling for the approved population.

Regulatory Status

FDA-approved as Vyleesi® (bremelanotide injection), approved June 21, 2019, specifically for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women — self-administered by subcutaneous injection as needed before anticipated sexual activity. This is a narrow, specific approval; it is not approved for men, for postmenopausal women, or for general libido enhancement, and using it outside its approved population/use is off-label.

What We Still Don't Know

Whether the Phase 3 results in premenopausal women with HSDD generalize to other populations being marketed off-label, and what the real safety/efficacy profile looks like outside the approved, FDA-reviewed dosing and population.

Limitations of Evidence

The strong Phase 3 evidence base is specific to premenopausal women with acquired, generalized HSDD. Extrapolation to other populations (men, postmenopausal women) or other goals is not supported by that same evidence and should be labeled as such — most of what's discussed online as "PT-141 for men" is off-label use without equivalent trial support.

Keep Researching

• Search ClinicalTrials.gov for PT-141 (Bremelanotide)
• Expert & Creator Library
• This Week in Peptides
• Understanding Your Bloodwork
• Related peptides:
  • Semaglutide
  • Tirzepatide